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Abstract
Background: The presence of Lewy bodies and Lewy neurites (LN) has been demonstrated in the enteric nervous system
(ENS) of Parkinson’s disease (PD) patients. The aims of the present research were to use routine colonoscopy biopsies (1) to
analyze, in depth, enteric pathology throughout the colonic submucosal plexus (SMP), and (2) to correlate the pathological
burden with neurological and gastrointestinal (GI) symptoms.
Methodology/Principal Findings: A total of 10 control and 29 PD patients divided into 3 groups according to disease
duration were included. PD and GI symptoms were assessed using the Unified Parkinson’s Disease Rating Scale part III and
the Rome III questionnaire, respectively. Four biopsies were taken from the ascending and descending colon during the
course of a total colonoscopy. Immunohistochemical analysis was performed using antibodies against phosphorylated
alpha-synuclein, neurofilaments NF 220 kDa (NF) and tyrosine hydroxylase (TH). The density of LN, labeled by anti-
phosphorylated alpha-synuclein antibodies, was evaluated using a quantitative rating score. Lewy pathology was apparent
in the colonic biopsies from 21 patients and in none of the controls. A decreased number of NF-immunoreactive neurons
per ganglion was observed in the SMP of PD patients compared to controls. The amount of LN in the ENS was inversely
correlated with neuronal count and positively correlated with levodopa-unresponsive features and constipation.
Conclusion/Significance: Analysis of the ENS by routine colonoscopy biopsies is a useful tool for pre-mortem neuropathological
diagnosis of PD, and also provides insight into the progression of motor and non-motor symptoms.
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Introduction
Normal function of the gastrointestinal (GI) tract relies both on
intrinsic reflexes and extrinsic control. The extrinsic innervation
depends on parasympathetic and sympathetic outputs. The
intrinsic innervation relies on the enteric nervous system (ENS),
an integrative neuronal network organized in two main plexuses,
myenteric and submucosal, that control bowel motility and
transmucosal fluid exchange, respectively [1]. A wide range of
GI diseases associated with motility dysfunction can be considered,
in part, as extrinsic and/or enteric neuropathies [2]. An emerging
concept is that the field of enteric neuropathies extends well
beyond digestive diseases, and that a subset of central nervous
system (CNS) disorders may present with concomitant alterations
of the ENS [3,4,5]. Among those, Parkinson’s disease (PD) is likely
to be a prime example because alterations of the ENS and GI
dysfunction have been described in the course of the disease [6].
Whether these alterations mirror brain pathology, and how they
relate to clinical symptoms, remain open questions.
PD is indeed much more than a selective degeneration of the
substantia nigra. The loss of nigral dopaminergic neurons is
responsible for the cardinal motor symptoms of PD (i.e.
bradykinesia and/or rest tremor), that are improved by dopamine
replacement therapy [7]. Yet PD patients also suffer from a wide
variety of dopa-unresponsive symptoms likely to reflect lesions
beyond the substantia nigra [8]. Most of the non-dopaminergic
symptoms appear or worsen with advancing age and disease
progression, and represent the majority of the disability observed
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symptoms, such as dysarthria, gait and postural instability, and
cognitive decline [10]. Among GI symptoms, chronic constipation
(CC) is by far the most frequent, affecting up to 60% of PD
patients [11].
The pathological hallmarks of PD are neuronal inclusions
termed Lewy bodies and Lewy neurites (LN) whose main
component is aggregated and phosphorylated alpha-synuclein
[12,13,14]. PD pathology concentrates in susceptible regions of the
CNS and peripheral autonomic nervous system, including the
ENS [15]. Lewy bodies within the ENS, first reported in 1984
[16], provide a putative anatomical basis for GI symptoms [17].
We have recently shown that whole-mounts of submucosa from
routine colonic biopsies allow a morphological analysis of the
submucosal plexus (SMP) [18,19]. Using this technique in a pilot
study, we have demonstrated that 4 out of 5 PDpatients display Lewy
pathology. Nevertheless, the small number of patients included did
not enable us to draw any clinicopathological correlations or to assess
the pathology in detail. We have therefore conducted the present
study in a larger set of 30 PD patients to allow in depth analysis of
enteric pathology throughout the colonic SMP, and to correlate the
extent of pathology with motor symptoms and constipation.
Methods
Subjects
PD patients aged 40–75 years were recruited over 24 months from
the movement disorder clinic in Nantes University Hospital, France.
Diagnosis was made according to the United Kingdom Parkinson’s
Disease Survey Brain Bank [20]. To limit recruitment bias and in
order to span the entire course of PD, 3 groups of patients divided
according to disease duration were included (group 1: #6y e a r s ,
group 2: 7–12 years and group 3: $13 years disease duration).
Healthy patients requiring a total colonoscopy for colorectal
cancer screening were included as controls. None of the control
subjects had a history of neurological or psychiatric diseases.
Patient evaluation
In PD patients, motor symptoms were assessed using the
Unified Parkinson’s Disease Rating Scale part III (UPDRS-III)
[21]. UPDRS-III was performed only in ON-state for group 1 and
in both OFF and ON-state for groups 2 and 3. OFF-state was
obtained following an overnight withdrawal of dopaminergic
treatment, and ON-state was reached one hour after intake of the
normal morning dose. Dopa-responsiveness was defined as the
percentage of UPDRS-III improvement compared with baseline.
UPDRS-III score was subdivided into an axial score (sum of items
18, 19, 22 and 27–30) that evaluates symptoms such as dysarthria
or postural instability [22].
Assessment of GI symptoms was performed using the Rome III
questionnaire. Chronic functional constipation was diagnosed as
defined by Rome III criteria [23]. The sum of the 6 constipation
items on the Rome III questionnaire (questions 9 to 14) was used
as a semi-quantitative score to assess the severity of CC.
All controls underwent a neurological examination to rule out PD
symptoms and cognitive deficiency. The study protocol was approved
by the local Committee on Ethics and Human Research (Comite ´d e
Protection des Personnes Ouest VI), and registered on Clinical-
Trials.gov (identifier NCT00491062). Written informed consent was
obtained from each patient and from each normal volunteer.
Colonoscopy biopsies
A total colonoscopy was performed according to the usual
procedure of the Gastroenterology department of Nantes Univer-
sity Hospital. In both patients and controls, 4 biopsies were taken
in the ascending colon and descending colon, respectively. Biopsies
were performed using standard biopsy forceps without needles
(FB210K, Olympus co., Japan). Samples were immediately
immersed in 4uC saline solution and processed as described.
Immunohistochemistry
Submucosa samples were processed for whole-mount immuno-
staining as described previously [18]. The primary antibodies used
were those directed against phosphorylated alpha-synuclein
(1:5000, WAKO, Osaka, Japan), neurofilament H 200 kDa (NF,
1:250, Chemicon, USA), Hu C/D (1:200, Invitrogen, Cergy
Pontoise, France), tyrosine hydroxylase (TH, 1:500, Pel-Freez,
USA) and dopamine-beta-hydroxylase (DBH, 1:250, Millipore,
USA). Suitable secondary antibodies conjugated to Alexa Fluor
488, 594 and 647 were used (Invitrogen, Cergy-Pontoise, France).
Neuronal cell counting and scoring
Neuronal counts were performed in one submucosa sample
from the ascending and descending colon, respectively. Hu or NF-
immunoreactive (IR) neurons were counted in all available ganglia
of the sample using a Zeiss Axiovert 200 M (Zeiss, Thornwood,
NY). The results were expressed as the average of the mean
number of neurons per ganglion in the two biopsies.
Density of phosphorylated alpha-synuclein inclusions was
evaluated after analyzing 2 biopsies from ascending and 2 from
descending colon. A biopsy was considered positive when
containing at least 1 LN. During the study, we used alternatively
a 3-category semi-quantitative scale based on the subjective
assessment of LN density in all 4 biopsies considered as a single
sample, and a quantitative rating scale based on the proportion of
positive biopsies (0: absent; +: 1/4 positive biopsy: moderate; ++: $2/
4 positive biopsies, severe pathology). As the two methods yielded
similar results (4/29 mismatches), we chose to present only the
quantitative rating scale because of its higher reproducibility.
Statistical analysis
Data are presented as mean 6 standard deviation. For
graphical representation of the total population of patients
(n=29) and controls (n=10), box plots were used in which the
end of the whiskers represent the minimum and maximum scores,
and ‘+’ sign represents the mean.
Regarding the number of neurons per ganglion, differences
between patients and controls were analyzed by unpaired two-
tailed Student’s t-tests. Differences between subgroups were
analyzed by two-way ANOVA followed by post hoc Newman–
Keuls tests.
For ordinal data (clinical scores), conventional Mann-Whitney
and Kruskal-Wallis tests followed by post hoc Dunn’s analyses
served to compare median magnitudes of change.
Correlation between Lewy pathology score and other param-
eters were assessed by Spearman test. Adjustment with age was
done with multiple linear regression. Chi square tests were used for
frequency analysis. For all statistical tests p,0.05 was deemed
significant.
Results
A total of 30 PD patients and 10 controls were recruited. Of
these 30 patients, one was excluded because of an error in the
processing of their biopsy. Patients were subdivided into groups
based on disease progression, resulting in similar group sizes (9 in
group 1, #6 years; 10 in group 2, 7–12 years; 10 in group 3, $13
years disease duration). Table 1 shows the main clinical features
Colonic Biopsies in PD
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e12728and pathological scores of all patients. Age and sex did not differ
significantly between patients and controls. CC, as defined by
Rome III criteria, affected one of the controls (10%) and 23 out of
29 PD patients (79%, p,0.001) (table 2).
Lewy neurites in colonic biopsies from PD patients
Twenty-one out of 29 PD patients (72%) displayed Lewy
pathology, in the form of Lewy neurites (LN) immunoractive (IR)
for both neurofilament (NF) and phosphorylated alpha-synuclein
(figure 1A–D, table 2). No immunoreactivity for phosphorylated
alpha-synuclein was observed within enteric neurons in controls,
with the exception of some faint somatic labeling that was present
in both patients and controls (data not shown). The proportion of
patients with Lewy pathology did not correlate with disease
progression (78% positive in group 1, 50% positive in group 2 and
90% positive in group 3).
LN were observed in isolated or bundled fibers (figure 1C–F).
Triple immunostaining experiments showed that 60% of the LN
were also IR for tyrosine hydroxylase (TH). Thirty-seven percent
of the LN were perivascular (figure 1GH), and 92% perivascular
LN were TH-IR (figure 1I–K). Additional experiments per-
formed in a subset of 6 positive PD patients (patients 16, 19, 22,
26, 28 and 29) showed that 51% of LN also expressed DBH
(figure S1). No cytoplasmic Lewy body labeling was observed.
72% of patients exhibited phosphorylated alpha-synuclein-positive
labeling (PS+ patients). However the pathological burden was
strikingly disparate between PS+ patients: some displayed
abundant LN in most samples, while others displayed only one
Table 1. Main clinical characteristics and immunohistochemical findings in patients.
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1 1F4 4 12–Y24 . 4 0
2 1M 6 7 21 1 –Y34 . 0 ++
3 1F7 2 21 0 –Y32 . 6 ++
4 1M 4 7 44–N03 . 5 +
5 1M 6 6 41–Y33 . 7 +
6 1F5 8 58–Y44 . 4 ++
7 1F5 6 53–N13 . 7 0
8 1M 5 8 65–Y34 . 8 +
9 1M 7 1 61 7 –N03 . 7 ++
10 2 M 63 8 5 70% N 1 4.0 0
11 2M 5 5 935 7 % Y23 . 5 +
12 2M 6 3 947 2 % Y43 . 1 +
13 2F6 4 95md* Y 2 4.4 0
14 2 M 66 9 4 77% Y 4 5.9 0
15 2 M 63 10 1 61% Y 3 3.8 +
16 2 F 65 10 5 41% Y 4 4.6 +
17 2 M 69 10 9 100% N 3 3.2 0
18 2 F 48 12 1 93% N 0 4.5 0
19 2 M 65 12 7 44% Y 3 2.6 ++
20 3 M 64 13 5 50% Y 4 2.6 +
21 3 F 66 13 9 78% Y 4 3.8 0
22 3 F 69 13 10 41% Y 3 3.4 ++
23 3 F 57 14 4 79% Y 3 3.9 +
24 3 F 68 14 1 72% Y 3 4.5 +
25 3 M 65 16 4 72% Y 6 2.5 ++
26 3 M 68 19 4 74% Y 4 2.6 ++
27 3 F 71 20 4 86% Y 2 3.6 +
28 3 M 72 20 21 29% Y 4 3.5 ++
29 3 M 60 24 13 57% Y 5 2.4 ++
*md: missing data.
doi:10.1371/journal.pone.0012728.t001
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LN was a more relevant marker than their mere presence/
absence, we used a quantitative Lewy pathology score. Group 0
represented the negative cases (n=8) while groups + (n=11) and
++ (n=10) represented moderate and severe Lewy pathology,
respectively.
Neurofilament and tyrosine hydroxylase-expressing
neurons in the submucosal plexus
In order to assess the suitability of NF as a neuronal marker in
human SMP, we first performed a double Hu and NF-
immunostaning in a subset of 3 control and 3 PD patients
(patients 9, 17 and 27). Anti-NF 200 kDa antibody virtually
labels all submucosal neurons in both conditions (figure S2),
thus allowing the use of NF-immunostaining for neuronal
count. Control submucosal samples displayed 4.360.8 NF-IR
neurons per ganglion. In PD, there was a decreased number of
NF-IR neurons per ganglion (3.760.8; p=0.04) (figure 2AB,
table 2).
When patients were separated into two groups according to the
presence (PS+) or absence (PS-) of phospho-synuclein IR neurites,
only PS+ patients had a significant drop in the amount of NF-IR
when compared to controls (p=0.01) (figure 2C). When PS+
patients were further stratified into subgroups with moderate (+)
and severe (++) pathology, there was a highly significant difference
in NF-IR between PS+ patients with severe pathology (++) and the
control group (p,0.01), and furthermore significant differences
were apparent between the severe pathology group and those with
absent (0) and moderate (+) pathology (p,0.05) (figure 2D). After
adjustment for age, a significant correlation remained between
Lewy score and the number of NF-IR neurons per ganglion
(p=0.02). There was no correlation between the number of
neurons per ganglion and age (p=0.193), nor between the number
of neurons per ganglion and disease duration (p=0.094), including
after age-adjustment (p=0.479).
Clinicopathological correlations
We then sought to correlate our two primary histological
findings, namely LN and the number of NF-IR neurons, with both
neurological and chronic constipation (CC) symptoms (table 3).
a. Neurological. In order to correlate Lewy pathology with
clinical features, we stratified patients according to the quantitative
Lewy pathology score, as described above. The Lewy pathology score
positively correlated with age (rS=0.395; p=0.03) (figure 3A). Age
is associated with worsening prognosis of PD [24], and as such is a
potential confounding factor. Therefore, all subsequent correlations
between Lewy pathology and disease severity were performed after
adjusting for age.
There was no correlation between pathology and disease
duration. Axial score was higher in the group with severe Lewy
pathology (++) when compared to the groups with absent (0) or
moderate (+) pathology (p,0.01) (figure 3B), and axial score
positively correlated with the Lewy pathology score (p=0.004).
Further reinforcing these findings, dopa-responsiveness negatively
correlated with the severity of pathological burden (p=0.0064).
The group devoid of LN was significantly more responsive to
levodopa than the groups with either moderate (p,0.05) or severe
(p,0.01) pathology (figure 3C). Conversely, the number of
neurons per ganglion did not correlate with either axial score or
dopa-responsiveness.
b. GastrointestinaI. CC was significantly more frequent
among PS+ (19/21) than among PS- patients (4/8) (p,0.05,
Fisher’s exact test). The severity of CC, as assessed by the
constipation score, positively correlated with the Lewy pathology
score (rS=0.381; p=0.042) (figure 3D). However, this correlation
was not significant after adjusting for age (p=0.17). There was no
correlation between the number of neurons per ganglion and CC
score (p=0.56).
Discussion
The four main outcomes of the present survey are (1) the
demonstration of LN in the SMP of 72% of PD patients, but in
none of the controls, (2) a higher frequency of constipation in LN-
positive patients, (3) a strong correlation between LN burden and
disease severity, (4) the possibility to readily and reproducibly
analyze the ENS in living patients, thereby providing an
opportunity to develop an original biomarker for PD.
Lewy pathology in the SMP of PD patients
A major finding of our study was the identification and
characterization of neuropathological lesions in the colonic
submucosa of PD patients. Lewy pathology in the SMP was
composed of LN only. This is consistent with a recent report in
which alpha-synuclein inclusions observed in the gastric submu-
cosa of deceased PD patients were LN, while Lewy bodies were
present in the soma of myenteric neurons [25]. The absence of
Lewy bodies in the SMP precludes affirmation that the SMP is
intrinsically affected by the pathological process. Indeed, Lewy
bodies and LN have been reported in colonic and gastric
myenteric neurons of deceased PD patients ([25] and our
unpublished results). In the guinea pig, myenteric neurons have
been shown to project to the SMP as well as to the submucosal
blood vessels [26].
Intrinsic dopaminergic neurons in the myenteric plexus are
altered in PD both in human [27] and animal models [28].
However, intrinsic dopaminergic neurons are a minority in the
colonic SMP [29]. At the level of the colonic SMP, the majority of
TH-IR neurites are noradrenergic sympathetic axons that also
express DBH (94% in our unpublished data). Our present results
show that 37% and 60% of LN are perivascular and TH-IR
Table 2. Comparison of main clinical and immunohistochemical variables between patients and controls.
Parameters Controls mean ± SD Parkinson’s mean ± SD p-value
Age 58.667.2 62.867.4 0.131
Gender (% male) 58.6% 60.0% 1.000
Chronic constipation 10% 79% 0.0002***
Neurons per ganglion 4.360.3 3.760.2 0.040*
Lewy neurites (% positive patients) 0% 72% 0.0001***
doi:10.1371/journal.pone.0012728.t002
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TH-IR LN belong to postganglionic sympathetic neurons. Thus, a
significant proportion of the enteric pathology reflects the
widespread sympathetic degeneration seen in other systems
[30,31].
LN in the SMP was present in 21 out of 29 PD patients. The
heterogeneity of PD with regard to peripheral autonomic
alterations was underscored by two recent autopsy-based studies
that found Lewy inclusions in the GI tract as well as in the
sympathetic network of nearly three-quarters of PD patients
Figure 1. Phospho-a-synuclein-positive submucosal neurites in PD patients. Labeling with antibodies against neurofilament (NF) (ACEGI)
and phosphorylated a-synuclein (BDFHJ) revealed that some NF-immunoreactive (IR) neurites were also phospho-a-synuclein-IR. Occasionally, these
phospho-a-synuclein-IR neurites were present amidst a submucosal ganglion (AB). Some of these structures formed bundles (D) while others were
isolated (arrowhead in F). Thirty seven percents of the phospho-a-synuclein-IR neurites were perivascular (GH). Triple immunostaining with
antibodies against tyrosine hydroxylase (K) revealed that 60% of LN were also TH-immunoreactive (IJK). Scale bar: 30 mm.
doi:10.1371/journal.pone.0012728.g001
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or disease severity will be further discussed.
Because of samples shortage, NF-co-immunostaining was
intended both for localizing phosphorylated alpha-synuclein
immunoreactivity within neurons and for neuronal counting,
taking advantage of NF somatic labeling. A significant decrease in
the number of NF-IR neurons was observed in the SMP of PD
patients. The significance of this finding is debatable since the
Figure 2. Count of neurofilament-positive neurons in the submucosal plexus of PD patients. A. Neurofilament-immunoreactive (NF-IR)
submucosal neurons were counted in every available ganglion from colonic biopsies. Representative photographs of ganglia from PD patients (left
panels) and controls (right panels). Scale bar: 30 mm. B. A significant decrease in the number of NF-IR neurons per ganglion was present in the SMP of
PD patients (PD, n=29) as compared to controls (CTL, n=10) (p,0.05). The bottom and the top of the box represent the 25th and 75th percentiles,
respectively, and the end of the whiskers represent the minimum and maximum values; the median is represented as a bar and the mean as a ‘+’ sign
inside the box. C. When segregating patients according to the presence (PS+) or absence (PS-) of phospho-synuclein IR neurites, the difference
between patients and controls was sustained only for the group with Lewy pathology (PS+, n=21, p,0.05). D. When further stratifying patients
according to the density of pathology, the difference between patients and controls was sustained only for the group with severe Lewy pathology
(++, n=10, p,0.01). Groups without (0) or with moderate pathology (+) significantly differed from the group with severe (++) pathology (p,0.05).
Each white square represents one control, each black circle represents one PD patient. Horizontal bars represent the mean. *p,0.05 and **p,0.01 as
compared with controls. #p,0.05 as compared with the group with severe pathology (++).
doi:10.1371/journal.pone.0012728.g002
Table 3. Clinico-pathological correlations.
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Spearman’s correlation with quantitative
score (p values)
0.034 * 0.290 0.008 ** 0.007 ** 0.042 * 0.004 ** 0
Age-adjusted correlation with quantitative
score (p values)
0.507 0.004 ** 0.006 ** 0.17 0.02 * 0
doi:10.1371/journal.pone.0012728.t003
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challenged in a recent study showing that as low as 43% of Hu-
IR neurons co-expressed NF in the myenteric plexus [33].
However in our experience, virtually all Hu-IR submucosal
neurons display somatic NF immunoreactivity (figure S2). This
discrepancy might result from differences in the expression of NF
between the submucosal and myenteric plexus and/or from
differences in the sensitivity of the antibodies that were used.
Although we cannot rule out phenotypic changes resulting in a
decreased expression of NF in a subset of neurons, it is tempting to
attribute the drop in NF-IR to neuronal loss. Whether enteric neuron
loss occurs in PD is still unclear. Two earlier studies performed on
biopsies and surgical samples failed to show any neuronal loss in the
colonic SMP of PD patients [19,27]. The low number of patients
assessed in these studies probably accounts for this discrepancy. If
enteric neurodegeneration occurs in the course of PD, the cardinal
neuropathology of the disease, namely neuronal death and Lewy
inclusions, would be recapitulated in the ENS, thereby mirroring the
lesions of affected brainstem nuclei in the CNS.
Lewy pathology burden and constipation
GI dysfunction stands among the most common non-motor
symptoms of PD. Symptoms such as dysphagia, nausea,
gastroparesis, and bowel dysfunction, including both reduced
bowel movement frequency and dyschesia, are a significant cause
of disability [34]. CC was significantly more frequent in the group
with than without LN, suggesting a pathogenic role for inclusions.
In this aspect however our study suffers from two potential
limitations. First, we did not use a validated constipation severity
score. Scores such as Patient Assessment of Constipation Symptoms
(PAC-SYM) questionnaire [35] might have revealed stronger
correlations between pathology burden and CC, while the correlation
we found did not remain significant after adjustment for age. Second
we did not assess the MP, which is directly involved in the control of
bowel motility. Whether the density of LN in the SMP is representative
o ft h ep a t h o l o g yb u r d e ni nt h eM Pi ss t i l la no p e nq u e s t i o nt h a tc o u l d
be addressed by a comparative and comprehensive analysis of the
myenteric and SMP in surgical or postmortem specimens.
Although controversial, CC has been linked to increased age-
related neurodegeneration in the ENS [36]. Loss of submucosal
neurons [37,38] and alterations of the sympathetic innervation
[39] in the ageing rat have been implicated in the pathophysiology
of CC, and a loss of myenteric neurons has been demonstrated in
the colon of patients with CC [40]. From our study, CC in PD
does not appear to be related with the number of submucosal NF-
IR neurons, and degeneration of sympathetic innervation might
play a role in this feature, since a significant proportion of LN
belonged to sympathetic outputs.
Lewy pathology burden is correlated with PD
progression
All patients included in this study had a comprehensive
neurological assessment. This enabled us to draw parallels between
pathological burden in the ENS and Parkinsonian symptoms.
Figure 3. Correlation of clinical symptoms with pathology burden. A. Measure of pathology burden using a quantitative score correlated
with age, which appeared as a potential confounding factor. Subsequent correlation analysis was performed after adjusting the data for age.
B. Pathology burden positively correlated with axial score, which measures axial symptoms such as dysarthria and postural instability. The group with
severe pathology (++) significantly differed from the group with absent (0) or moderate (+) pathology (p,0.01). C. Pathology burden also correlated
with L-Dopa responsiveness, estimated by the percentage of UPDRS-III improvement after L-Dopa intake. Responsiveness was higher in the group
with absent pathology (0), as compared with the group with moderate (+,p ,0.05) or severe (++,p ,0.01) pathology. D. Pathology burden also
correlated with constipation severity, as defined by the number of positive answers to the constipation items of Rome III questionnaire. Each black
circle represents one PD patient. Horizontal bars represent the mean. *p,0.05 and **p,0.01 as compared with the group with absent pathology (0).
#p,0.05 and ##p,0.01 as compared with the group with severe pathology (++).
doi:10.1371/journal.pone.0012728.g003
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the presence of dopa-unresponsive axial symptoms, such as
dysarthria or postural instability but not with disease duration
and motor symptoms. Two recent studies relating autonomic
dysfunction with the clinical phenotype of PD provided similar
results [41,42]. Clinical scores of autonomic symptoms, postural
blood pressure response impairment [41] and myocardial
123I-
metaiodobenzylguanidine uptake [42] weakly correlated with
disease duration and motor symptom severity. Conversely, the
presence of axial symptoms was associated with greater autonomic
dysfunction. These studies, together with our results, strongly
suggest that functional and structural alterations in the enteric and
autonomic nervous systems are associated with the presence of
axial motor symptoms. Interestingly, a recent survey searching for
patterns of coherency among the full clinical spectrum of PD
found that dysautonomic, axial and cognitive symptoms co-
segregated and best characterized disease severity [43]. In an
individual patient, the appearance of axial symptoms is predictive
of disease progression toward dementia [10] and is thought to
reflect the spreading of pathology to non-dopaminergic structures
of the brainstem, forebrain and cortex [44]. Thus, the heteroge-
neity of PD regarding dysautonomia in general, and alterations of
the ENS in particular, might reflect in part different degrees of
severity.
The ENS as biomarker in PD
Routine colonic biopsies can be used to provide examination of
the submucosal enteric neurons in living patients [45]. Here we
confirm on a large scale that such a procedure allows a safe and
reliable analysis of the ENS. Total colonoscopy is a simple
diagnostic procedure with a low risk of adverse effects [46].
Accordingly, no complications occurred in the 40 patients
included in the present study, either during or after the procedure.
The skin and the olfactory epithelium contain neuronal
networks affected by Lewy pathology during PD that are also
accessible by routine biopsies and have recently been evaluated as
histopathological markers for PD [30,47]. However, the results of
these works were disappointing since only 2 out of 20 PD patients
displayed LN in skin biopsies and no alpha-synuclein aggregates
were present in the biopsied olfactory epithelium of 7 Parkinsonian
patients [48,49]. Consequently, our study is the first to show that
Lewy pathology can be reproducibly analyzed using biopsies from
a peripheral tissue in living patients.
The ENS displays specific features that make it a prime
candidate for being a histopathological marker of PD (for review
see [50]). In contrast to the skin and olfactory epithelium, colonic
biopsies allow the retrieval and analysis of a dense integrated
neuronal network, not only neuronal processes [18]. Using optical
recording techniques, electrophysiological properties of submuco-
sal neurons from colonic biopsies can be studied [51]. Therefore,
analysis of the ENS during the progression of PD may represent a
unique opportunity to monitor PD pathology and its impact on
neuronal function in living patients. We have shown in the present
survey that the pathological burden in the ENS is correlated to the
presence of dopa-unresponsive axial symptoms, strongly support-
ing the use of colonic biopsies as a biomarker for the assessment of
PD severity. Their use for the positive diagnosis of incipient or
even preclinical PD still requires to test the specificity of enteric
submucosal LN in larger series and to improve the sensitivity of
the technique. Possible strategies include an increased number of
colonic samples or the use of upper digestive tract biopsies, which
add the potential risk of inhalation during the endoscopy.
Braak and coworkers have postulated that the ENS is affected
early by Lewy pathology during the course of PD, even before the
pathology is apparent in the substantia nigra. This suggests that
the ENS heralds the onset of a pathological process that further
spreads to the CNS via autonomic innervation of the gut [25,52].
Although tempting, this theory relies only on correlations
performed in autopsy studies and is still a matter of debate. By
demonstrating the presence of LN in the colon at early stages (78%
of patients ,6 years), our findings do not refute this hypothesis.
We believe that the use of colonic biopsies, by enabling analysis of
the ENS in PD patients at a very early stage of the disease, will be
helpful for validating or refuting Braak’s hypothesis.
In conclusion, the ENS can be considered not only as ‘the
second brain’ [53], but also as a window towards the ‘first’ brain.
The ENS probably antedates the CNS in evolutionary terms, and
its complexity challenges its central counterpart, especially since
the functional and chemical diversity of enteric neurons closely
resembles that of the CNS [54]. Enteric neuropathies recapitulate
many aspects of neurological diseases [2]. In particular, degener-
ative changes occur in the aging gut [55]. In this context, it is
hardly surprising that enteric neurons can mirror central
alterations in neurodegenerative disorders. It is possible that
further studies may expand this concept to other neurodegener-
ative diseases. For example, the presence of hyperphosphorylated
tau aggregates in myenteric neurons of aging rats suggests that
tauopathies such as Alzheimer’s disease may also affect the ENS
[56]. We consider our method to represent a major advance in the
search for biomarkers for PD. The use of the, as yet unrecognized,
ENS as a window into the CNS represents an original approach,
with implications that may well extend beyond PD.
Supporting Information
Figure S1 51% of phospho-a-synuclein-positive submucosal
neurites express DBH. Labeling with antibodies against dopa-
mine-beta-hydroxylase (DBH) (BDF) and phosphorylated a-
synuclein (ACE) revealed that some DBH-immunoreactive (IR)
neurites were also phospho-a-synuclein-IR. In a subset of 6 PD
patients, the proportion of Lewy neurites that expressed DBH was
51%. Perivascular Lewy neurites in EF. Scale bar 30 mm.
Found at: doi:10.1371/journal.pone.0012728.s001 (3.90 MB
PDF)
Figure S2 Evaluation of neurofilament immunostaining as a
pan-neuronal marker in human submucosal plexus. Labeling with
antibodies against neurofilament 200 kDa (NF) (ACEGIK) and
Hu C/D (BDFHJL) revealed that virtually all submucosal
neurons, whether isolated (EF and KL) or in submucosal ganglia
containing .2 neurons, coexpress NF and Hu C/D. Sample
images from 3 controls (A–F) and 3 PD patients (G–L). Note the
nuclear expression of Hu in L, a pattern that is occasionally seen in
patients and controls. Scale bar 30 mm.
Found at: doi:10.1371/journal.pone.0012728.s002 (8.13 MB
PDF)
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